GKOSbenzinga

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Summary

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on February 24, 2025 by benzinga

    FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery | GKOS Stock News | Candlesense